Compare Sezzle Inc (SEZL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Sezzle Inc trades at $128.64 (market cap $3.95B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.6× Sezzle Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sezzle Inc for 15 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SEZL | XBI | |
|---|---|---|
Market Cap | $3.95B | $10.11B |
Volume | 550,075 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $188.55 | $169.55 |
52-Week Low | $50.97 | $104.99 |
Typical Hold Time | 15 Days | 38 Days |
Enterprise Value | $3.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SEZL stock is trading at $128.64, up 12.99% in the past 24 hours, showing strong momentum with a bullish technical signal. The company demonstrates exceptional profitability with 72.36% gross margins and 30.35% net income margins, while recent earnings have consistently beaten expectations. Analyst consensus remains strongly positive with a $168 price target representing significant upside potential from current levels.
SEZL presents a compelling growth opportunity with robust financial metrics and strong analyst support, though investors should monitor competitive pressures in the BNPL sector and the stock's current technical overbought conditions. The company's expanding product portfolio and subscriber growth provide fundamental support for continued appreciation.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
